Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up

What happened: Teva reported third-quarter 2026 adjusted earnings of 86 cents per share and revenue of $4.40 billion, both beating consensus estimates, and raised its 2026 revenue guidance. Key numbers: Adjusted EPS 86 cents vs 72 cents estimate, up 10.2% year over year. Revenue $4.40 billion vs $4.24 billion estimate, down 2% year over year. Why it matters: Growth in branded drugs Austedo, Ajovy and Uzedy offset a 39% decline in U.S. generic/biosimilar revenues, and the raised outlook reflects momentum across the innovative portfolio. Market: +2.4% today ($63.19), +19.4% YTD, 0.4x vol — as of 18:33 UTC Coverage: 4 outlets in 24h

Teva reported third-quarter 2026 adjusted earnings of 86 cents per share and revenue of $4.40 billion, both beating consensus estimates, and raised its 2026 revenue guidance.

Growth in branded drugs Austedo, Ajovy and Uzedy offset a 39% decline in U.S. generic/biosimilar revenues, and the raised outlook reflects momentum across the innovative portfolio. Market: +2.4% today ($63.19), +19.4% YTD, 0.4x vol — as of 18:33 UTC